Discover a new way to find and share stories you'll love… Learn about Reading Desk

All Blogs / Industries / Medical / Popular


Get More Specific:

Genteel Lancing Device for Pain-Free Glucose Testing Anywhere on Body (VIDEO)

Diabetics checking their blood sugar levels usually have to prick their finger to get a sufficient draw for the glucometer to do its job. Some newer glucometers work with smaller blood samples and are able to take blood from the inside of the arm where there are fewer nerves to cause pain. Show More Summary

The most news I’ve ever gotten out of Meditech

If you think Epic Systems, which doesn’t issue press releases and infrequently shares much with the press, is tough for the media, you should try Meditech. I’ve never gotten a response from anyone there and never written any actual news about the company. Show More Summary

Glaser to focus on interoperability as Cerner SVP

A big question surrounding Cerner’s $1.3 billion acquisition of Siemens Health Services has been answered: John Glaser, head of the health IT division of Siemens AG, will join Cerner as a senior vice president, concentrating on  “driving...Show More Summary

AstraZeneca: How Many Approvals, Again?

So AstraZeneca says that they're expecting "8 to 10 " approvals in 2015-2016. Has anyone ever done that? Even close? I take it that this whole press release is there to pump up investors and keep Pfizer from coming back and making another bid for them, but although the company does have a lot of stuff going on, this just seems wildly optimistic. Show More Summary

Cost to Bring a New Drug to Market Is $2.6 Billion According to Tufts - 3X More Than in 2003!

According to a new study by the Tufts Center for the Study of Drug Development (CSDD), which receives funding from the pharmaceutical industry, the estimated cost to develop a new Rx drug for marketing in the U.S. is $2,558 million or $2.6 billion (see press release). Show More Summary

Can writing about medicine change medicine for the better?

I’m getting to the point where I think it might be time to stop or at least decelerate the pace of my writing on medicine. When I retired from medical practice almost a year ago there were a lot of pent up experiences that I felt a need write about. But now I have already written about […]

#WWBR Week of November 10, 2014

This week: patient engagement, Partners faces resistance, handoffs getting structured, and more. Read more ›

Wait, We Didn't Tell You About That Endpoint?

Hmm. Via Twitter, we find this interesting example of moving the goalposts. NeoStem, a small stem-cell company, announced results the other day for a trial of their cardiac stem cell therapy. One bearish trader who'd been following them...Show More Summary

What does a good death mean to you?

In July 1991, I was beginning my first year of medical school in Rochester, New York. I was filled with excitement and anxiety on beginning a journey in medicine as I started on the road to becoming a doctor. At that time, Rochester was in the national spotlight because of the actions of one of […]

TMS Azide Explosions

There's been a lot of safety on the blog this week. One recent accident I haven't talked about is an azide explosion at Minnesota - C&E News, though, has plenty of coverage. Back in June, a grad student was injured when a batch of trimethylsilyl azide exploded - a 200 gram batch. Show More Summary

Chemical Myths

Several folks on my Twitter feed have mentioned a new book coming out from Springer, 100 Chemical Myths. I haven't seen a copy, but it's supposed to "deals with popular yet largely untrue misconceptions and misunderstandings relatedShow More Summary

How Not to Do It: NMR Magnets

Here's an NMR imaging blog with details of a recent problem in an Indian facility. Two people ended up stuck to the machine, pinned by an oxygen cylinder (!) that one of them brought into the room. Both sustained injuries. There areShow More Summary

Allergan Escapes Valeant

The Allergan / Valeant saga has come to an end, with Allergan fighting them off by doing a deal to be taken over by Actavis. No word yet on whether they'are going to let Allergan keep the invisible golf course. Valeant is, of course,...Show More Summary

Vytorin Actually Works

The data from the IMPROVE-IT trial on cardiovascular outcomes for Vytorin have been released. And the combination met the primary endpoint: fewer heart attacks and strokes compared to those already on statin therapy alone. Matthew Herper has an excellent roundup of the results and their context. Show More Summary

Fatalities at DuPont

As many readers will have heard, there was a fatal accident at a DuPont plant in the Houston area over the weekend. Four workers were killed by methyl mercaptan (methanethiol), and here's more on what happened. As is often the case,Show More Summary

The New York TImes on Drug Discovery

The New York Times Magazine has a piece on the current problems with drug discovery. I was interviewed by the author, and get I quoted at one point. Nothing in the article will amaze any regular reader here, but it's probably the first...Show More Summary

The November 2014 HIT Standards Committee

The November HIT Standards Committee focused on “asynchronous bilateral cutover” - the compatibility of different CCDA payloads, healthcare IT that supports long term services and support, an update on the Standards & Interoperability...Show More Summary

How Are Things at Princeton?

So how's the new chemistry building at Princeton working out? I last asked for comments four years ago, but I'm prompted to do so again by this post by Luysii, who has been hearing that the building isn't necessarily working out as planned. Show More Summary

Unity Farm Journal Second Week of November 2014

The mood at Unity Farm has been somber this week with the death of my father-in-law on Sunday. He was a significant part of seasonal farm activities and was a kind of third parent to my daughter. His death from pancreatic cancer wasShow More Summary

Phage-Derived Catalysts

I've been enjoying this recent paper in JACS, but then I always like to see intersections of molecular biology with organic synthesis. The authors, from CUNY and the University of Strathclyde, are using a phage display library to see if they can come up with displayed peptide combinations that are catalytic. Show More Summary

Copyright © 2011 Regator, LLC